<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864083</url>
  </required_header>
  <id_info>
    <org_study_id>11-177</org_study_id>
    <nct_id>NCT01864083</nct_id>
  </id_info>
  <brief_title>FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients</brief_title>
  <official_title>FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate
      how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or
      PEM can accurately measure your response to chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">August 29, 2017</completion_date>
  <primary_completion_date type="Actual">August 29, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess the diagnostic accuracy</measure>
    <time_frame>2 years</time_frame>
    <description>Accuracy of standardized uptake values will be analyzed by receiver operating characteristic (ROC) curves. ROC curves will be constructed separately for FACBC PET, FACBC PEM and MR. The area under the curve will be used as a summary measure and compared using the standard nonparametric test [20]. We will also consider dichotomizing the uptake and present accuracy using sensitivity, specificity and predictive values. Dichotomized values will be compared using the McNemar test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ability of FACBC PET and PEM to determine therapeutic response to neoadjuvant chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with locally advanced IDC or ILC, requiring neoadjuvant therapy prior to definitive surgery, will undergo FACBC PET and PEM both before chemotherapy and after. Following definitive breast surgery, pathologic specimens will be analyzed to determine if FACBC imaging can predict pathologic treatment response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission mammography (PEM) When available</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MR</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC

          -  No prior therapy for IDC or ILC

          -  Clinical need for local disease staging with breast MR (Group A only)

          -  Clinical need for neoadjuvant chemotherapy (Group B only)

          -  Patients must provide written informed consent

        Exclusion Criteria:

          -  Age &lt;21 years

          -  Men

          -  Pregnancy or lactation

          -  Patients who have already started treatment for the current malignancy

          -  Patients who cannot undergo PET scanning (i.e. because of weight limits)

          -  Patients who are known to have contraindication for MRI (e.g. metal implants)

          -  Patients may only participate in group #1 or group #2, but not both
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Ulaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FACBC PET/PEM</keyword>
  <keyword>MR</keyword>
  <keyword>11-177</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

